The adrenergic receptor antagonist Carvedilol (cas 72956-09-3) interacts with serotonin 2A receptors both in vitro and in vivo
-
Add time:07/13/2019 Source:sciencedirect.com
There is increasing support for the potential clinical use of compounds that interact with serotonin 2A (5-HT2A) receptors. It is therefore of interest to discover novel compounds that interact with 5-HT2A receptors. In the present study, we used computational chemistry to identify critical ligand structural features of 5-HT2A receptor binding and function. Query of compound databases using those ligand features revealed the adrenergic receptor antagonist Carvedilol (cas 72956-09-3) as a high priority match. As carvedilol is used clinically for cardiovascular diseases, we conducted experiments to assess whether it has any interactions with 5-HT2A receptors. In vitro experiments demonstrated that carvedilol has high nanomolar affinity for 5-HT2A receptors. In vivo experiments demonstrated that carvedilol increases the ethanol-induced loss of the righting reflex and suppresses operant responding in mice, and that these effects are attenuated by pretreatment with the selective 5-HT2A receptor antagonist M100907. Moreover, carvedilol did not induce the head-twitch response in mice, suggesting a lack of psychedelic effects. However, carvedilol did not activate canonical 5-HT2A receptor signaling pathways and antagonized serotonin-mediated signaling. It also reduced the head-twitch response induced by 2,5-Dimethoxy-4-iodoamphetamine, suggesting potential in vivo antagonism, allosteric modulation, or functional bias. These data suggest that carvedilol has functionally relevant interactions with 5-HT2A receptors, providing a novel mechanism of action for a clinically used compound. However, our findings do not clearly delineate the precise mechanism of action of carvedilol at 5-HT2A receptors, and additional experiments are needed to elucidate the role of 5-HT2A receptors in the behavioral and clinical effects of carvedilol.
We also recommend Trading Suppliers and Manufacturers of Carvedilol (cas 72956-09-3). Pls Click Website Link as below: cas 72956-09-3 suppliers
Prev:Synthesis of NIR fluorescent thienyl-containing aza-BODIPY and its application for detection of Hg2+: Electron transfer by bonding with Hg2+
Next:Carvedilol (cas 72956-09-3) blockage of delayed rectifier Kv2.1 channels and its molecular basis) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Enhancement of oral bioavailability of poorly water soluble Carvedilol (cas 72956-09-3) by chitosan nanoparticles: Optimization and pharmacokinetic study07/22/2019
- Solidification of Carvedilol (cas 72956-09-3) loaded SMEDDS by swirling fluidized bed pellet coating07/20/2019
- Prophylactic use of Carvedilol (cas 72956-09-3) to prevent ventricular dysfunction in patients with cancer treated with doxorubicin07/21/2019
- Carvedilol (cas 72956-09-3) attenuates experimentally induced silicosis in rats via modulation of P-AKT/mTOR/TGFβ1 signaling07/19/2019
- Carvedilol (cas 72956-09-3) and thyroid hormones co-administration mitigates oxidative stress and improves cardiac function after acute myocardial infarction07/18/2019
- Comparative study of Carvedilol (cas 72956-09-3) and quinidine for inhibiting hKv4.3 channel stably expressed in HEK 293 cells07/17/2019
- Soluplus®, Eudragit®, HPMC-AS foams and solid dispersions for enhancement of Carvedilol (cas 72956-09-3) dissolution rate prepared by a supercritical CO2 process07/16/2019
- The cardioprotective effects of Carvedilol (cas 72956-09-3) on ischemia and reperfusion injury by AMPK signaling pathway07/15/2019
- Carvedilol (cas 72956-09-3) blockage of delayed rectifier Kv2.1 channels and its molecular basis07/14/2019
-
Health and Chemical more >
-
Related Products